UNSPSC 51384533: Naproxen sodium

This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H13O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9TN87S3A3C, chemically known as 2-naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (s)- but more generally known as naproxen sodium, which bears US NIH Compound Identifier 1302. European Medicines Agency schedules Naproxen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03392MIG.

Most nations, for tariff and trade purposes, schedule naproxen sodium under HS 29189900 and SITC 51396. As of Q4 2014, NAPROXEN SODIUM remains US FDA's Preferred Term for this commodity. Naproxen sodium bears US NLM identifiers UMLS ID C0546873 and NCI Concept Code C48006. SMILES: C[C@@H](C1CCC2CC(CCC2C1)OC)C(=O)[O-].[NA+].

UNSPSC 51384533 Naproxen sodium is a Commodity code that state and local governments use to classify over-the-counter pain relief medications, though the recent procurement activity tagged under this code shows a significant mismatch with its nominal scope. The single recent opportunity in the record—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and safe drug deactivation systems for community health support, products unrelated to naproxen sodium. The mismatch suggests either a tagging error in the source data or inconsistent application of the code across jurisdictions. Based on available evidence, this code shows little relevant recent activity aligned with its pharmaceutical definition.

Seminole County posted the naloxone and drug deactivation systems solicitation on June 30, 2026, with an IFB response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The contract carries a two-year initial term with a one-year renewal option and requires vendors to meet standard compliance obligations including E-Verify certification, drug-free workplace attestation, and federal environmental regulations tied to potential FEMA funding. Without additional recent opportunities properly aligned with naproxen sodium procurement, geographic spread cannot be characterized beyond this single Florida instance, and issuing-body patterns remain unclear.